Literature DB >> 6575177

Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside.

M L Slevin, A Johnston, R C Woollard, E M Piall, T A Lister, P Turner.   

Abstract

The degree of binding of a drug to plasma proteins has a marked effect on its distribution, elimination, and pharmacological effect. Since only the unbound fraction is available for distribution into extravascular space, the ratio of drug in cerebrospinal fluid (CSF) or saliva to that in plasma is often regarded as a physiological measure of the free fraction of a drug. CSF: plasma and saliva: plasma ratios of cytosine arabinoside (araC) have been measured in patients with acute leukaemia and found to be 0.1-0.28, implying a binding of 72-90%. The protein binding of araC was measured by equilibrium dialysis in the plasma of patients with acute leukaemia at presentation. The mean binding ratio was 2.3 +/- 6.8, implying that there was little or no protein binding. There was no correlation between alpha-1 acid glycoprotein (AAG) levels and protein binding. The low CSF and saliva: plasma araC ratios found, suggest that drugs such as araC which have low lipid solubility do not pass freely into extravascular space. Thus the CSF or saliva: plasma ratio cannot be considered a good physiological measure of protein binding for drugs with poor lipid solubility.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6575177      PMCID: PMC1439160          DOI: 10.1177/014107688307600507

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  10 in total

1.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

2.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Authors:  D H Ho; E Frei
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

3.  Intrathecal arabinosyl cytosine in meningeal leukemia.

Authors:  J J Wang; C B Pratt
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

Review 4.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy.

Authors:  M L Slevin; E M Piall; G W Aherne; A Johnston; T A Lister
Journal:  Med Pediatr Oncol       Date:  1982

6.  Treatment of central nervous system leukemia with intrathecal cytosine arabinoside.

Authors:  P R Band; J F Holland; J Bernard; M Weil; M Walker; D Rall
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

7.  Techniques for plasma protein binding of demethylchlorimipramine.

Authors:  L Bertilsson; R Braithwaite; G Tybring; M Garle; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

8.  Cerebrospinal fluid concentrations of propranolol, pindolol and atenolol in man: evidence for central actions of beta-adrenoceptor antagonists.

Authors:  E A Taylor; D Jefferson; J D Carroll; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

9.  Cytosine arabinoside binding to human plasma proteins.

Authors:  H C van Prroijen; G Vierwinden; J Wessels; C Haanen
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-10

10.  A radioimmunoassay for cytosine arabinoside.

Authors:  E M Piall; G W Aherne; V M Marks
Journal:  Br J Cancer       Date:  1979-10       Impact factor: 7.640

  10 in total
  1 in total

1.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.